Currently, NACT is recommended as a standardtreatment modality in the management of locallyadvanced breast cancer, early-stage patients who arenot suitable for breast-conserving surgery, and HER-2 positive or triple negative subgroups with tumours≥2 cm [2]. The gene discussed is ERBB2; the disease is breast cancer.